findmyKOL

Mikkael Sekeres, MD, MSc

Enriched profile

Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine · Sylvester Comprehensive Cancer Center

ORCIDNPI
Region🇺🇸 Miami, FL · Southeast · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Mikkael Sekeres is Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine at Sylvester Comprehensive Cancer Center. OpenAlex indexes 1,453 publications with 37,894 citations (h-index 92); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Mikkael A. Sekeres, MD, is Chief, Division of Hematology, and Professor of Medicine with Tenure, Department of Medicine, University of Miami Miller School of Medicine at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Department of Medicine, Division of Hematology. The public record shows 1,453 publications with 37,894 citations (h-index 92), centered on Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 22 companies.

  • Most recent indexed publication: 2026 · Leukemia
  • Top research focus: Acute Myeloid Leukemia Research
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 22 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
MDS / MPN9 trialsLeukemia (AML/ALL/CML/CLL)5 trialsLeukemia, Myeloid, Acute2 trialsMyeloproliferative Disorders1 trialLeukemia, Erythroblastic, Acute1 trialCytopenia1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research

Drugs & molecules

across trials, industry payments and publications
Reblozylgeneric · LuspaterceptClinical trials1Industry payments2Publications2Vanflytageneric · QuizartinibClinical trialsIndustry payments10Publications2AzacitidineClinical trials2Industry paymentsPublications8

Works with

trial sponsors and companies reporting payments
Daiichi Sankyo Inc.Clinical trialsIndustry payments11AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments7Celgene CorporationClinical trialsIndustry payments7

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,453publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

37,894citations

Total citations across indexed works.

92h-index

Hirsch index (OpenAlex). i10-index 401.

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials
22companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record
1 more sourced public position behind the reveal.Reveal →

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    90.8%
    BCL-2 Inhibitor35.1%
    Venclexta100%
    Part D12 patients
    Kinase inhibitor29.8%
    Imatinib Mesylate69%Tasigna31%
    Part D<11 patients
  • Anti-infectives

    9.2%
    Fluoroquinolone Antibacterial9.2%
    Levofloxacin100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Jaroslaw P. Maciejewski554Rami S. Komrokji305Anjali S. Advani267

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/mikkael-sekeres-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/mikkael-sekeres-93a648231

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    mikkaelsekeres.com/about-me

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mikkaelsekeres.com
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/sylvestercancer/p/C6rVuu7LGjo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • Facebook

    m.facebook.com/SylvesterCancer/videos/meet-dr-mikkael-a-sekeres-dr-sekeres-chief-of-hematology-at-sylvester-explains-h/345427397602383

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →m.facebook.com
  • Apple Podcasts

    podcasts.apple.com/us/podcast/cancer-stories-the-art-of-oncology/id1365887382

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com
7 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chief

    Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu
  • Professor of Medicine with Tenure

    University of Miami Miller School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.miami.edu
  • Chair

    ASH Treatment Guidelines for Older Adults with Acute Myeloid Leukemia (AML)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
  • Elected Councillor

    American Society of Hematology (ASH) Executive Committee, four-year term beginning after the 2025 ASH Annual Meeting

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eurekalert.org
  • Leadership in Science Award

    Aplastic Anemia and MDS International Foundation (AAMDSIF)

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org

Secondary affiliations

appointments beyond the home institution
  • Former Professor of Medicine

    Director of the Leukemia Program, and Vice Chair for Clinical Research, Cleveland Clinic Taussig Cancer Institute

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org
  • Physician Liaison in Hematology / co-Chair

    Medical Advisory Board, Aplastic Anemia and MDS International Foundation (AAMDSIF), since 2004

    2004
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org
  • Member

    American Society of Clinical Oncology (ASCO)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.